Travoprost is a potent FP receptor agonist that finds clinical use as an ocular hypotensive agent for the treatment of glaucoma. Travoprost is manufactured at Cayman Pharma, our Czech subsidiary. GMP material, which conforms to the USP Monograph, is available. The DMF is on file with the US FDA, Canada, India, Japan, China, in several EU member states, and in several other countries.